Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 3/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.34 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25767688 | 0.90 | FOLH1 (0.41) | MMP2BMP1ADAMTS5ADAMTS4MMP8 | |
| SCHEMBL27103261 | 0.84 | CCKBR (0.42) | BMP1PSMB5CCKBRPSMB8 | |
| SCHEMBL27424227 | 0.83 | MMP2 (0.41) | MMP2MMP9 | |
| SCHEMBL22316575 | 0.80 | FOLH1 (0.55) | BMP1FOLH1RIMKLANAALAD2 | |
| SCHEMBL21728970 | 0.80 | BMP1 (0.32) | BMP1ADAMTS5ADAMTS4CCKBR | |
| SCHEMBL19483448 | 0.80 | FOLH1 (0.42) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL22316500 | 0.80 | FOLH1 (0.42) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL18804751 | 0.80 | FOLH1 (0.42) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL22315438 | 0.79 | FOLH1 (0.50) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL22315883 | 0.79 | BMP1 (0.42) | BMP1ADAMTS5ADAMTS4FOLH1RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | MMP8, SLC11A2, NFKBIA | MMP2 71/4885MMP9 188/4885BMP1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.